Updated MAY 2009
The Leukemia & Lymphoma Society is a collaborator for the following clinical trials,
To find out more about these clinical trials or to contact somone regarding eligibility, continue reading:
1) A Phase 1-2, Multicenter, Open-Label Study of AEG35156 in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia and Indolent B-Cell Lymphomas
Aegera's antisense compound AEG35156 has shown early evidence of activity in patients with advanced indolent B-cell lymphomas in Phase 1 trials and merits further evaluation in this disease. This trial is designed to determine the recommended dose of AEG35156 in patients with relapsed or refractory chronic lymphocytic leukemia (CLL) and indolent B-cell lymphomas.
Primary Outcome Measures:
- Objective tumor response according to CLL NCI-WG criteria
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00768339
Canada, Alberta
Tom Baker Cancer Centre Calgary, Alberta, Canada, T2N 4N2
Contact: Nizar J Bahlis, MD, 403-944-1564, nizarbah@cancerboard.ab.ca
Contact: Kelly Mclachlan, 403-521-3520, kellymcl@cancerboard.ab.ca
Principal Investigator: Nizar J Bahlis, MD
| Recruiting |
Canada, Ontario
Princess Margaret Hospital Toronto, Ontario, Canada, M5G 2M9
Contact: Christine Chen, MD, christine.chen@uhn.on.ca
Sub-Investigator: Aaron Schimmer, MD
Sub-Investigator: John Brandwein, MD
| Recruiting |
United States, Ohio
The Cleveland Clinic, Taussig Cancer Institute Cleveland, Ohio, United States, 44195
Contact: John Sweetenham, MD, 216-445-6707
Principal Investigator: John Sweetenham, MD
| Not yet recruiting |
2) A Phase Ib Study of ISF35 in Combination With Chemotherapy (FCR) in Subjects With Relapsed, Refractory, and/or 17p- CLL
The study is a Phase 1b open label, non-randomized, single institution clinical trial that is designed to evaluate the safety and tolerability of three repeat infusions of ISF35 followed by a standard regimen of three cycles of fludarabine, cyclophosphamide and rituximab (FCR) in subjects with refractory, resistant, and/or 17p- CLL.
Memgen's ISF35 has already been used in two Phase I clinical trials. The trials demonstrated that ISF35 treatment is well tolerated and patients did not experience any significant or unexpected adverse events. Patients reported flu-like symptoms from ISF35, which disappeared within one to three days.
The trials also showed that ISF35 stimulates the immune system to act against CLL cells and sensitize leukemic cells to subsequent treatment. Repeat infusions of ISF35 administered as a single agent to subjects with CLL resulted in durable reductions in circulating and lymph-node bound leukemic cells. Furthermore, CLL patients with 17p deletion responded to standard courses of FCR after receiving ISF35 and achieved durable remissions.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00772486
Contacts
Contact: Denise Darrah, RN, 858-822-5375, ddarrah@ucsd.edu
Contact: Mary Carpenter, 858-822-5635, mcarpenter@ucsd.edu
Location
United States, California
University of California, San Diego Moores Cancer Center San Diego, California, United States, 92093
Contact: Denise Darrah, RN, 858-822-5375, ddarrah@ucsd.edu, Principal Investigator: Januario Castro, MD
| Recruiting |
3) Trial of CPX-351 in Adult Patients With First Relapse Acute Myeloid Leukemia (AML)
The study investigates if CPX-351 will be a) more effective than the standard intensive salvage AML treatment and b) more tolerable than the standard intensive salvage treatment regimens.
The study compares the investigational product CPX-351 vs the standard intensive salvage treatment for first relapse AML patients.
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00822094
United States, New York
Weil Cornell Medical Center New York, New York, United States, 10021
Contact: Tania Curcio, 212-746-2571, tjc9003@med.cornell.edu
Principal Investigator: Eric Feldman, MD
| Recruiting |
United States, Texas
M.D. Anderson Cancer Center Houston, Texas, United States, 77030
Contact: Jody Hiteshew, RN, 712-792-9192, jhiteshe@mdanderson.org
Principal Investigator: Jorge Cortes, MD
| Recruiting |
4) Everolimus and Bortezomib in Treating Patients With Relapsed or Refractory Mantle Cell or Other Indolent Non-Hodgkin Lymphoma
The rationale behind this study is to see that everolimus and bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. This phase I trial is studying the side effects and best dose of everolimus when given together with bortezomib in treating patients with relapsed or refractory mantle cell or other indolent non-Hodgkin lymphoma.
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00671112
United States, Ohio
Case Comprehensive Cancer Center Cleveland, Ohio, United States, 44106-5065
Contact: Clinical Trials Office - Case Comprehensive Cancer Center, 800-641-2422
| Recruiting |
For additional information on clinical trials for blood cancer patients, see the Clinical Trials section of www.LLS.org.
To search clinical trial opportunities, log onto the LLS TrialCheck®.
The Leukemia & Lymphoma Society Clinical Trial Service Disclaimer
Information you receive about LLS sponsored clinical trials or through the LLS Clinical Trial Service is not intended to be complete or exhaustive, nor is it a substitute for the advice of your physician. Therefore, it is important to discuss the included information with your physician. Due to clinical trial protocols and specific eligibility criteria, the listings may change and/or may no longer be actively accruing patients.
Your physician is the only one who can determine if you meet the specific eligibility criteria listed in these trials. The search that was performed was a general search based on the information that was given. If you and your physician decide that you may benefit from one of the studies, your physician will need to contact the principal investigator in charge of the study to discuss your medical history and current health status.
LLS does not provide medical or other healthcare opinions or services. The enclosure of another organization's / hospital's resource(s) does not indicate or imply that LLS endorses, recommends, or favors the enclosed information.
If you have any questions, please don't hesitate to call the IRC at (800) 955-4572, 9 a.m. to 5 p.m., ET.
print page
email page
